VistaGen Therapeutics to Present at 11th Annual Biotech Showcase
27 déc. 2018 08h30 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 27, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central...
VistaGen Therapeutics Receives Hong Kong Patent for Methods of Production for AV-101
29 nov. 2018 08h30 HE
|
VistaGen Therapeutics, Inc.
New Hong Kong patent complements counterpart patents previously issued in China, Europe and the U.S. SOUTH SAN FRANCISCO, Calif., Nov. 29, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ:...
VistaGen Therapeutics Receives Notices of Allowance in Australia and Japan for AV-101 Patents Covering Treatment of Depression
12 nov. 2018 08h30 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central...
VistaGen Therapeutics Reports Fiscal 2019 Second Quarter Financial Results
29 oct. 2018 16h30 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central...
VistaGen Therapeutics Acquires Worldwide Rights to Develop and Commercialize PH10, a First-in-Class Intranasally Administered Neuroactive Steroid with Rapid-onset Antidepressant Effects for Major Depressive Disorder Demonstrated in Phase 2a Study
25 oct. 2018 09h00 HE
|
VistaGen Therapeutics, Inc.
PH10 demonstrated in Phase 2a study significant antidepressant effects without psychological side effects after only one week of administration SOUTH SAN FRANCISCO, Calif., Oct. 25, 2018 (GLOBE...
VistaGen Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018
22 oct. 2018 08h30 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central...
VistaGen Therapeutics Appoints Dr. Michael Liebowitz to CNS Clinical and Regulatory Advisory Board in Preparation for Pivotal Phase 3 Development of PH94B as the First Rapid-Acting, On-Demand Treatment of Social Anxiety Disorder
15 oct. 2018 08h30 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central...
VistaGen Therapeutics Receives FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic Pain
03 oct. 2018 08h30 HE
|
VistaGen Therapeutics, Inc.
Designation highlights serious unmet need for new treatment options for patients suffering from neuropathic pain Second FDA Fast Track designation for AV-101 since December 2017 marks another...
VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals for As-Needed Treatment of Social Anxiety Disorder
13 sept. 2018 08h30 HE
|
VistaGen Therapeutics, Inc.
Phase 3-ready asset expands VistaGen’s CNS pipeline and complements its neuropsychiatry focus on Major Depressive Disorder (MDD) with AV-101 Novel PH94B nasal spray expected to enter pivotal Phase 3...
VistaGen Therapeutics Reports Fiscal 2019 First Quarter Financial Results
14 août 2018 16h49 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Aug. 14, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for...